Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.

Gopal M, Padayatchi N, Metcalfe JZ, O'Donnell MR.

Int J Tuberc Lung Dis. 2013 Aug;17(8):1001-7. doi: 10.5588/ijtld.12.0144. Epub 2013 Mar 25. Review.

2.

Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.

Hwang TJ, Dotsenko S, Jafarov A, Weyer K, Falzon D, Lunte K, Nunn P, Jaramillo E, Keshavjee S, Wares DF.

BMJ Open. 2014 Jan 2;4(1):e004143. doi: 10.1136/bmjopen-2013-004143. Review.

3.

Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.

Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, Koh WJ.

Clin Infect Dis. 2008 Aug 15;47(4):496-502. doi: 10.1086/590005.

PMID:
18611154
4.

Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China.

Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G, Li M, Li F, Wu M, Zhu Y, Sun H, Gu J, Wang X, Zhang Z.

Clin Infect Dis. 2015 May 1;60(9):1361-7. doi: 10.1093/cid/civ027. Epub 2015 Jan 20.

PMID:
25605283
5.

Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.

Blöndal K, Viiklepp P, Guðmundsson LJ, Altraja A.

Int J Tuberc Lung Dis. 2012 Sep;16(9):1228-33. doi: 10.5588/ijtld.12.0037. Epub 2012 Jun 28.

PMID:
22748131
6.

Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drug-resistant Mycobacterium tuberculosis isolates.

Horita Y, Takii T, Yagi T, Ogawa K, Fujiwara N, Inagaki E, Kremer L, Sato Y, Kuroishi R, Lee Y, Makino T, Mizukami H, Hasegawa T, Yamamoto R, Onozaki K.

Antimicrob Agents Chemother. 2012 Aug;56(8):4140-5. doi: 10.1128/AAC.06445-11. Epub 2012 May 21.

7.

In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates.

Zhang Z, Li T, Qu G, Pang Y, Zhao Y.

Int J Antimicrob Agents. 2015 Jan;45(1):71-5. doi: 10.1016/j.ijantimicag.2014.09.012. Epub 2014 Oct 18.

PMID:
25459737
8.

Multidrug- and extensively drug-resistant tuberculosis, Germany.

Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R, Hoffmann H, Kirsten D, Schaberg T, Ruesch-Gerdes S, Lange C; German TBNET Group.

Emerg Infect Dis. 2008 Nov;14(11):1700-6. doi: 10.3201/eid1411.080729.

9.

[A study on the activity of clofazimine with antituberculous drugs against Mycobacterium tuberculosis].

Lu Y, Wang B, Zhao WJ, Zheng MQ, Li P, Fu L, Liang BW.

Zhonghua Jie He He Hu Xi Za Zhi. 2010 Sep;33(9):675-8. Chinese.

PMID:
21092635
10.

Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.

Park SK, Kim JH, Kang H, Cho JS, Smego RA Jr.

Int J Infect Dis. 2009 Mar;13(2):170-5. doi: 10.1016/j.ijid.2008.06.001. Epub 2008 Sep 2.

11.

Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: an update.

Chaiprasert A, Srimuang S, Tingtoy N, Makhao N, Sirirudeeporn P, Tomnongdee N, Theankeaw O, Charoensook S, Leechawengwongs M, Prammananan T.

Int J Tuberc Lung Dis. 2014 Aug;18(8):961-3. doi: 10.5588/ijtld.13.0197.

PMID:
25199012
12.

Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study.

Padayatchi N, Gopal M, Naidoo R, Werner L, Naidoo K, Master I, O'Donnell MR.

J Antimicrob Chemother. 2014 Nov;69(11):3103-7. doi: 10.1093/jac/dku235. Epub 2014 Jun 30.

13.

Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China.

Yuan X, Zhang T, Kawakami K, Zhu J, Zheng W, Li H, Deng G, Tu S, Liu W.

BMC Infect Dis. 2013 Jul 12;13:315. doi: 10.1186/1471-2334-13-315.

14.

WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.

Chang KC, Yew WW, Tam CM, Leung CC.

Antimicrob Agents Chemother. 2013 Sep;57(9):4097-104. doi: 10.1128/AAC.00120-13. Epub 2013 Jun 17. Review.

16.

Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB.

Martins M, Viveiros M, Couto I, Amaral L.

Int J Tuberc Lung Dis. 2009 May;13(5):569-73. Review.

PMID:
19383188
17.

Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis.

Kempker RR, Kipiani M, Mirtskhulava V, Tukvadze N, Magee MJ, Blumberg HM.

Emerg Infect Dis. 2015 Jun;21(6):992-1001. doi: 10.3201/eid2106.141873.

18.

New treatment options for multidrug-resistant tuberculosis.

Field SK, Fisher D, Jarand JM, Cowie RL.

Ther Adv Respir Dis. 2012 Oct;6(5):255-68. Epub 2012 Jul 4. Review.

PMID:
22763676
19.

[Management of multidrug-resistant tuberculosis].

Tritar F, Daghfous H, Ben Saad S, Slim-Saidi L.

Rev Pneumol Clin. 2015 Apr-Jun;71(2-3):130-9. doi: 10.1016/j.pneumo.2014.05.001. Epub 2014 Aug 19. Review. French.

PMID:
25153927

Supplemental Content

Support Center